Adaptimmune Therapeutics PLC

Research Adaptimmune Therapeutics PLC (473A) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker473A
• ExchangeSTU
• CurrencyEUR
• Financial periodQ2 2025
• RevenueEUR 13.68M
• Net income-EUR 30.34M
• Free cash flow-EUR 34.86M
• Gross margin81.7%